• Clinical Trials - Age related macular degeneration

    Study Objective Contact
    Protocol GX29176: A Phase III Multicenter, Randomized, Double-Masked Sham-Controlled Study to Assess the Efficacy and Safety of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration [LCID Study Number: 2014-061] The purpose of this study is to compare the effects, good or bad, of lampalizumab versus sham injection on you and your geographic atrophy (GA) and also to see if lampalizumab works differently in people with specific inherited (genetic) characteristics with an increased risk of AMD Principal Investigator(s):
    Jeffrey Chang, MD, MMS

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Christine A. Gould, MMSc, PAC.
    Protocol OPH1003: A Phase 3 Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista™(anti PDGF-b pegylated aptamer) Administered in Combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Subfoveal Neovascular Age-Related Macular Degeneration [LCID Study Number: 2013-066] The objectives of this study are to evaluate the safety and efficacy of an investigational drug Fovista„§ when administered in combination with the FDA-approved drug Lucentis„¥ compared to Lucentis„¥ alone in patients with abnormal blood vessels in the back of the eye due to wet age-related macular degeneration (AMD). Both Fovista„§ and Lucentis„¥ are given by injection into the vitreous which is the clear, jelly-like substance that fills the middle of the eye. Principal Investigator(s):
    Gregory R. Blaha, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Christine A. Gould, MMSc, PAC.
    Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients with Neovascular Age-Related Macular Degeneration: CEDAR STUDY [LCID Study Number: 2015-058] The purpose of this study is to investigate the safety and effectiveness of an investigational drug called abicipar on patients who have been diagnosed with “wet” age related macular degeneration. The effects of this drug will be compared with another, FDA approved drug called Lucentis. Researchers will also measure the body’s immune response while on these drugs while measuring the amount of antibodies that have formed in the participant’s blood. Patients who are enrolled will come in for study visits every four weeks for the length of the study, which is approximately 24 months. Principal Investigator(s):
    Gregory R. Blaha, MD, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Christine A. Gould, MMSc, PAC.